Avigen Awarded £300K Grant to Accelerate Cell Therapy R&D Innovation London, UK – 1 April 2025 – Avigen (“the Company”), a privately held Contract Research Organisation spun out from Imperial College London developing advanced preclinical immunotherapy R&D services using its proprietary…
Avigen Raises £300k from SFC Capital to Launch Immunotherapy CRO Services
Avigen Raises £300k from SFC Capital to Launch Immunotherapy CRO Services London, UK – 31 March 2025 – Avigen (“the Company”), a privately held Contract Research Organisation spun out from Imperial College London developing advanced preclinical immunotherapy R&D services using its…